alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
axdx_ex1013.htm

EXHIBIT 10.13

 

REVOLVING LINE OF CREDIT PROMISSORY NOTE

 


	
Amount: $__________
	
 
	
Date: _____, 2016




 

WHEREAS, the Borrower desires to borrow funds from the Lender from time to time and the parties desire to enter into a note which provides for advances from time to time on an unsecured basis.

 

THEREFOR, FOR VALUE RECEIVED, CO-DIAGNOSTICS, INC. a Utah corporation, (referred to as the "Borrower") promises to pay to MACHAN 1988 PROPERTY TRUST, a Utah trust, ( referred to as the "Lender"), or order, at its address the sum of _________________ or the aggregate unpaid principal balance of all advances made to the Borrower by Lender pursuant to this Note from time to time ("Advances"), whichever is less, on _______ 2016 ("Matu1ity Date") in lawful money of the United States and in immediately available funds, with interest on the unpaid p1incipal balance of this Revolving Line of Credit Note ("Note") at the rate of Twelve percent (12 %) per annum and shall be computed on the basis of a 360 day year.

 

All Advances made pursuant to this Note shall be made in the sole discretion of the Lender and Lender may refuse to make additional Advances at any time and for any reason.

 

The principal balance and all accrued but unpaid interest is due in full on the Maturity Date.

 

If the final payment due under this Note is not paid on its due date or within fifteen (15) days thereafter, or if the Borrower otherwise defaults under the terms of this Note, then the holder hereof may accelerate this Note and declare the entire balance due and owing whereupon the Borrower agrees to pay the entire balance of the Note upon demand.

 

Each payment shall be applied first to the payment of interest and thereafter to the payment of principal. In the event of non-payment of any interest, the final payment or the accelerated principal in the event of default, the Borrower agrees to pay all expenses of collection of this Note, including reasonable attorney' s fees and court costs incurred in any proceeding including any proceedings in the United States Bankruptcy Court. After acceleration, in the event of default, and after the due date and before and after judgment, this Note shall accrue interest at the rate of 18% per annum for each day after the Maturity Date that the principal amount remains unpaid until paid.

 

This Note shall be governed by the laws of the State of Utah.

 

Every maker, endorser or guarantor of this Note waives presentment, demand, notice, protest and all other notices in connection with the deliver, acceptance, default or enforcement of this Note and each agrees that the holder, from time to time, may renew, modify or extend performance of obligations hereunder without their consent.

 

IN WITNESS WHEREOF, the Borrower has caused this Note to be executed as of the date above set forth.

 

 


	 	
BORROWER:

 

CO-DIAGNOSTICS, INC.

a Utah corporation
	
	 	 	 	 
	 	by		
	
 
	
 
		 
	 	its
§ 226.102 Master-formula and batch-production records. ( a ) For each Type A medicated article(s) master-formula records shall be prepared, endorsed, and dated by a competent and responsible individual and shall be independently checked, reconciled, endorsed, and dated by a second competent and responsible individual. The record shall include: ( 1 ) The name of the Type A medicated article(s) and a specimen copy of its label.
( 2 ) The weight or measure of each ingredient, adequately identified, to be used in manufacturing a stated weight of the Type A medicated article(s).
( 3 ) A complete formula for each batch size, or of appropriate size in the case of continuous systems to be produced from the master-formula record, including a complete list of ingredients designated by names or codes sufficiently specific to indicate any special quality characteristics; an accurate statement of the weight or measure of each ingredient, except that reasonable variations may be permitted in the amount of ingredients necessary in the preparation of the Type A medicated article(s), provided that the variations are stated in the master formula; an appropriate statement concerning any calculated excess of an ingredient; and a statement of the theoretical yield.
( 4 ) Manufacturing instructions for each type of Type A medicated article(s) produced on a batch or continuous operation basis, including mixing steps and mixing times that have been determined to yield an adequately mixed Type A medicated article(s); and in the case of Type A medicated article(s) produced by continuous production run, any additional manufacturing directions including, when indicated, the settings of equipment that have been determined to yield an adequately mixed Type A medicated article(s) of the specified formula.
( 5 ) Control instructions, procedures, specifications, special notations, and precautions to be followed.
( b ) A separate batch-production and control record shall be prepared for each batch or run of Type A medicated article(s) produced and shall be retained for at least 2 years after distribution by the manufacturer has been completed. The batch-production and control record shall include: ( 1 ) Product identification, date of production, and endorsement by a competent and responsible individual.
( 2 ) Records of each step in the manufacturing, packaging, labeling, and controlling of the batch, including dates, specific identification of drug components used, weights or measures of all components, laboratory-control results, mixing times, and the endorsements of the individual actively performing or the individual actively supervising or checking each step in the operation.
( 3 ) A batch number that permits determination of all laboratory-control procedures and results on the batch and all lot or control numbers appearing on the labels of the Type A medicated article(s).
EXHIBIT 10.04(e)(3)

                            RESOLUTIONS ADOPTED AT A
                                 MEETING OF THE
                               BOARD OF DIRECTORS
                                       OF
                         COMMUNITY CARE OF AMERICA, INC.
                                January 30, 1997



                     RESOLVED,  that  Section  3.1  of  the  Community  Care  of
           America, Inc. Supplemental Deferred Compensation Plan (the "Plan") is
           hereby  amended  by  deleting  therefrom  the fifth  sentence  in its
           entirety (which sentence begins with the words  "Notwithstanding  the
           preceding,"),  so that a Change  of  Control  will not  result  in an
           increase in the amount of the Employer  Contribution  Credit credited
           to a Participant's account; and

                     FURTHER  RESOLVED,  that  Section 5.2 of the Plan is hereby
           amended to delete the provision therein which is to the effect that a
           Participant  shall  become  100% vested in his or her account if such
           Participant  terminates  employment  with the  Company for any reason
           within one year following a Change of Control; and

                     FURTHER RESOLVED, that the president and any executive vice
           president of the Company be, and each of them hereby is,  authorized,
           empowered and directed,  in the name and on behalf of the Company, to
           executive and deliver such documents,  agreements,  and  instruments,
           and to do or cause to be done all such  other  acts or things as each
           of them may deem necessary or appropriate to effect the intent and to
           accomplish  the purposes of the  transactions  contemplated  by these
           resolutions, the taking of any such actions to be conclusive evidence
           of the authority granted hereby.
#### § 1316.61 Exceptions to rulings.

Exceptions to rulings of the presiding officer are unnecessary. It is sufficient that a party, at the time the ruling of the presiding officer is sought, makes known the action that he desires the presiding officer to take, or his objection to an action taken, and his grounds therefor.
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsThermal System Sizing Comparison of a PEM and Solid Oxide Fuel Cell Systems on MarsPower production is a key aspect to any Mars mission. One method for providing power throughout the day/night cycle, or to satisfy short-duration high-output power needs, is to utilize a regenerative fuel cell system for providing energy storage and nighttime or supplemental power. This study compares the total system mass for two types of fuel cell systems, proton exchange membrane (PEM) and solid oxide (SO), sized to provide 10 kW of electrical output power in the Mars environment. Two operating locations were examined; one near the equator at 4 Â°S latitude and one the higher northern latitude of 48Â°N. The systems were sized to operate throughout the year at these locations, where the radiator was sized for the worst-case warm condition and the insulation was sized for the worst-case cold condition. Using the selected system parameters, the results for both latitudes showed that the lightest system was the SO fuel cell with a PEM electrolyzer. This was mainly due to the higher operational temperature of the SO system enabled a significantly smaller radiator mass compared to that of the PEM fuel cell system. However, there was a significant difference in mass for the PEM system when operated near the equator as compared to the higher northern latitude. For the 10-kW output system this difference in mass was just under 100 kg.Document ID20190001449Acquisition SourceGlenn Research CenterDocument TypeTechnical Memorandum (TM)AuthorsColozza, Anthony J.*(Vantage Partners, LLC Brook Park, OH, United States)*Jakupca, Ian J.*(NASA Glenn Research Center Cleveland, OH, United States)*Date AcquiredMarch 12, 2019Publication DateFebruary 1, 2019Subject CategorySpacecraft Propulsion And PowerReport/Patent NumberNASA/TM-2019-220019GRC-E-DAA-TN62192Funding Number(s)WBS: WBS 469947.04.27.22CONTRACT_GRANT: NNC12BA01BDistribution LimitsPublicCopyrightPublic Use Permitted.KeywordsFuel CellsRegenerative Fuel CellsElectrolysisSurface Power SystemsAvailable DownloadsNameType20190001449.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1141b Ammonium phosphate, dibasic. ( a ) Ammonium phosphate, dibasic ((NH4)2HPO4, CAS Reg. No. 7783-28-0) is manufactured by reacting ammonia with phosphoric acid at a pH above 5.8.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), p. 21, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a dough strengthener as defined in § 170.3(o)(6) of this chapter; a firming agent as defined in § 170.3(o)(10) of this chapter; a leavening agent as defined in § 170.3(o)(17) of this chapter; a pH control agent as defined in § 170.3(o)(23) of this chapter; and a processing aid as defined in § 170.3(o)(24) of this chapter.
( 2 ) The ingredient is used in food at levels not to exceed current good manufacturing practice.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[48 FR 52440, Nov. 18, 1983]
<PAGE>   1
                                                                    Exhibit 23.1


                          Consent of Ernst & Young LLP
                              Independent Auditors


We consent to the incorporation by reference in the Registration Statement
(Form S-8 No. 333-50987) pertaining to the Independence Community Bank 401(k)
Savings Plan in RSI Retirement Trust (the "Plan") of our report dated April
30, 1999, with respect to the consolidated financial statements of
Independence Community Bank Corp., included in the Form 10-K for the year
ended March 31, 1999.


                                                /s/Ernst & Young LLP

New York, New York
June 25, 1999
Editorial Note on Part 14
Editorial Note: Nomenclature changes to part 14 appear at 88 FR 45065, July 14, 2023.

§ 14.140 Establishment of a color additive advisory committee. The Commissioner will establish a color additive advisory committee under the following circumstances: ( a ) The Commissioner concludes, as a matter of discretion, that it would be in the public interest for a color additive advisory committee to review and make recommendations about the safety of a color additive on which important issues are pending before FDA and for interested persons to present information and views at an oral public hearing before a color additive advisory committee.
( b ) There is an issue arising under section 721(b)(5)(B) of the FD&C Act concerning the safety of a color additive, including its potential or actual carcinogenicity, that requires the exercise of scientific judgment and a person who would be adversely affected by the issuance, amendment, or repeal of a regulation listing a color additive requests that the matter, or the Commissioner as a matter of discretion determines that the matter should, be referred to a color additive advisory committee. ( 1 ) Paragraph (b) does not apply to any issue arising under the transitional provisions in section 203 of the Color Additive Amendments of 1960 relating to provisional listing of commercially established colors. A color additive advisory committee to consider any such matter will be established under paragraph (a) of this section.
( 2 ) A request for establishment of a color additive advisory committee is to be made in accordance with § 10.30. The Commissioner may deny any petition if inadequate grounds are stated for establishing a color additive advisory committee. A request for establishment of a color additive advisory committee may not rest on mere allegations or denials, but must set forth specific facts showing that there is a genuine and substantial issue of fact that requires scientific judgment and justifies a hearing before a color additive advisory committee. When it conclusively appears from the request for a color additive advisory committee that the matter is premature or that it does not involve an issue arising under section 721(b)(5)(B) of the FD&C Act or that there is no genuine and substantial issue of fact requiring scientific judgment, or for any other reason a color additive advisory committee is not justified, the Commissioner may deny the establishment of a color additive advisory committee.
( 3 ) Establishment of a color additive advisory committee on the request of an interested person is conditioned upon receipt of the application fee specified in § 14.155.
( 4 ) Any person adversely affected may request referral of the matter to a color additive advisory committee at any time before, or within 30 days after, publication of an order of the Commissioner acting upon a color additive petition or proposal.
# L_2018240EN.01000201.xml

| 25.9.2018 | EN | Official Journal of the European Union | L 240/2 |
| --- | --- | --- | --- |

25.9.2018

EN

Official Journal of the European Union

L 240/2

---

COUNCIL IMPLEMENTING REGULATION (EU) 2018/1284

of 24 September 2018

implementing Regulation (EU) 2017/1509 concerning restrictive measures against the Democratic People's Republic of Korea

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Council Regulation (EU) 2017/1509 of 30 August 2017 concerning restrictive measures against the Democratic People's Republic of Korea and repealing Regulation (EC) No 329/2007 (1), and in particular Article 47(5) thereof,

Having regard to the proposal of the High Representative of the Union for Foreign Affairs and Security Policy,

Whereas:

| (1) | On 30 August 2017 the Council adopted Regulation (EU) 2017/1509. |
| --- | --- |

(1)

On 30 August 2017 the Council adopted Regulation (EU) 2017/1509.

| (2) | On 14 September 2018 the United Nations Security Council (‘UNSC’) Committee established pursuant to UNSC Resolution 1718 (2006) amended the listing of one vessel subject to restrictive measures. |
| --- | --- |

(2)

On 14 September 2018 the United Nations Security Council (‘UNSC’) Committee established pursuant to UNSC Resolution 1718 (2006) amended the listing of one vessel subject to restrictive measures.

| (3) | Annex XIV to Regulation (EU) 2017/1509 should therefore be amended accordingly, |
| --- | --- |

(3)

Annex XIV to Regulation (EU) 2017/1509 should therefore be amended accordingly,

HAS ADOPTED THIS REGULATION:

Article 1

Annex XIV to Regulation (EU) 2017/1509 is amended as set out in the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the date of its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 24 September 2018.

For the Council

The President

J. BOGNER-STRAUSS

---

(1)  
  OJ L 224, 31.8.2017, p. 1.

1

---

ANNEX

In Annex XIV to Regulation (EU) 2017/1509, entry 32 under the heading ‘B. Vessels which are prohibited entry into ports’ is replaced by the following:

| ‘32. | Name: WAN HENG 11

  Additional information

  IMO: 8791667
  M/V WAN HENG 11 engaged in a ship-to-ship transfer, likely for oil, with M/V RYE SONG GANG 1 on 13 February 2018.
  Wan Heng 11, formerly a Belize-flagged vessel, is now operating as a DPRK-flagged vessel named the KUMJINGANG3 or Kum Jin Gang 3.’ |
| --- | --- |

‘32.

Additional information

IMO: 8791667

M/V WAN HENG 11 engaged in a ship-to-ship transfer, likely for oil, with M/V RYE SONG GANG 1 on 13 February 2018.

Wan Heng 11, formerly a Belize-flagged vessel, is now operating as a DPRK-flagged vessel named the KUMJINGANG3 or Kum Jin Gang 3.’

---
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Employment Outlook for Elementary and Secondary School Teachers

              																	Taylor, Cora E.					 and 	United States. Bureau of Labor Statistics. 						*Employment Outlook for Elementary and Secondary School Teachers : Bulletin of the United States Bureau of Labor Statistics, No. 972*,												Washington: 								U.S. Govt. Print. Off., 										1949,									https://fraser.stlouisfed.org/title/4386,			accessed on September 25, 2024.						    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS FINANCIAL INFORMATION EXTRACTED FROM THE AUDITED MARCH
31, 1998 FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          MAR-31-1998
<PERIOD-END>                               MAR-31-1998
<CASH>                                          59,022
<SECURITIES>                                         0
<RECEIVABLES>                                1,433,121
<ALLOWANCES>                                    60,966
<INVENTORY>                                          0
<CURRENT-ASSETS>                             1,700,422
<PP&E>                                       1,959,193
<DEPRECIATION>                               1,469,026
<TOTAL-ASSETS>                               2,684,157
<CURRENT-LIABILITIES>                        1,708,358
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        32,147
<OTHER-SE>                                   9,205,706
<TOTAL-LIABILITY-AND-EQUITY>                 2,684,157
<SALES>                                      1,747,398
<TOTAL-REVENUES>                             3,883,962
<CGS>                                                0
<TOTAL-COSTS>                                1,519,623
<OTHER-EXPENSES>                             3,025,050
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             158,063
<INCOME-PRETAX>                                174,626
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            174,626
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   174,626
<EPS-PRIMARY>                                     0.06
<EPS-DILUTED>                                     0.05
        

</TABLE>